The Lyme disease vaccine: conception, development, and implementation.
In the past 20 years, remarkable strides have been made toward understanding and preventing Lyme disease in humans. In December 1998, the U.S. Food and Drug Administration approved a recombinant outer surface protein A vaccine against Lyme disease (LYMErix, SmithKline Beecham, Philadelphia, Pennsylvania). The vaccine, which is derived from a lipidated outer surface protein of the causative spirochete Borrelia burgdorferi, is important because it may decrease the morbidity and financial costs associated with Lyme disease. Its mechanism is unique because it works inside the tick vector itself, preventing the human from becoming infected.
Thanassi
W T
WT
Section of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut 06519, USA.
Schoen
R T
RT
D000818:Animals; D000954:Antigens, Surface; D001179:Arthropod Vectors / Q000382:microbiology; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D006801:Humans; D018884:Ixodes / Q000382:microbiology; D008074:Lipoproteins; D008193:Lyme Disease / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein